Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2


Autoria(s): SANTOS, Raul D.; WATERS, David D.; TARASENKO, Lisa; MESSIG, Michael; JUKEMA, J. Wouter; FERRIERES, Jean; VERDEJO, Juan; CHIANG, Cheng-Wen; L-TAP 2 Investigators
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background Differences between women and men have been documented for both diagnostic testing and treatment in cardiology. This analysis evaluates whether low-density lipoprotein cholesterol (LDL-C) success rates according to current guidelines and high-density lipoprotein cholesterol (HDL-C) levels differ by gender in the L-TAP 2 population. Methods Patients aged >= 20 years with dyslipidemia on stable lipid-lowering therapy were assessed in 9 countries between September 2006 and April 2007. Low-density lipoprotein cholesterol goal attainment by cardiovascular risk level and region and determinants of low HDL-C were compared between genders. Results Of 9,955 patients (45.3% women) evaluated, women had a significantly lower overall LDL-C success rate than men (71.5% vs 73.7%, P = .014), due entirely to the difference in the high-risk/coronary heart disease (CHD) group (LDL-C goal <100 mg/dL, 62.6% vs 70.6%, P < .0001) Among CHD patients with >= 2 additional risk factors, only 26.7% of women and 31.5% of men (P = .021) attained the optional LDL-C goal of <70 mg/dL. High-density lipoprotein cholesterol was <50 mg/dL in 32.2% of women and <40 mg/dL in 26.8% of men (P < .0001), including 38.2% of women and 29.8% of men in the high risk/CHD group (P < .0001). Predictors of low HDL-C in women included diabetes, smoking, waist circumference, and hypertension. Conclusions Cholesterol treatment has, improved substantially since the original L-TAP a decade ago, when only 39% of women attained their LDL-C goal. However, high-risk women are undertreated compared to men, and a substantial opportunity remains to reduce their cardiovascular risk. (Am Heart J 2009; 158:860-6.)

Identificador

AMERICAN HEART JOURNAL, v.158, n.5, p.860-866, 2009

0002-8703

http://producao.usp.br/handle/BDPI/21214

10.1016/j.ahj.2009.08.009

http://dx.doi.org/10.1016/j.ahj.2009.08.009

Idioma(s)

eng

Publicador

MOSBY-ELSEVIER

Relação

American Heart Journal

Direitos

restrictedAccess

Copyright MOSBY-ELSEVIER

Palavras-Chave #CORONARY-HEART-DISEASE #CARDIOVASCULAR-DISEASE #STATIN TREATMENT #RISK-FACTORS #MANAGEMENT #HEALTH #PREVENTION #CARE #ATORVASTATIN #METAANALYSIS #Cardiac & Cardiovascular Systems
Tipo

article

original article

publishedVersion